Hormone therapy: time for replacement?

Time to review all the evidence for hormone replacement therapy.

The meta-analysis by Bath and Gray provides evidence that hormone replacement therapy does not confer any protection against stroke in postmenopausal women but increases their risk of stroke. These observations add to a rapidly expanding literature on the potential hazards and benefits of the therapy. The women’s health initiative trial contributes well over half of the current trial data, and ...

Hormone replacement therapy.

HRT is indicated for the treatment of moderate ▪ to severe vasomotor and urogenital symptoms associated with menopause. HRT is not recommended for primary prevention of ▪ disease because of increased risk of other adverse events. The use of HRT increases the risk of stroke, venous ▪ thromboembolism (VTE) and gall bladder disease and combined oestrogen progestogen therapy is also associated with...

Hormone replacement therapy.

Postmenopausal hormone replacement therapy.

Several comprehensive accounts of postmenopausal hormone replacement treatment have been published in the United Kingdom in the past year`so in this review we concentrate on areas which, while often controversial, are of concern to the practising physician. We discuss the effects of postmenopausal hormone replacement therapy on the risks of developing coronary heart disease, osteoporosis, and c...

Subcutaneous hormone replacement therapy.

It is estimated that 75% of women are in an acute estrogen deficiency state within a few years after the onset of the menopause. Every woman inevitably reaches this phase except for a fortunate few who have some source of endogenous estrogens available to them. We believe it would be prudent to offer hormone replacement therapy to every woman with symptoms of the menopause, and to those in whom...